BioCentury
ARTICLE | Clinical News

Biogen, Eisai's elenbecestat reduces plaques, slows AD progression in Phase II

July 27, 2018 6:53 PM UTC

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) reported data from the Phase II Study 202 for their β-site APP-cleaving enzyme 1 (BACE1) inhibitor elenbecestat (E2609) showing that the therapy reduced amyloid plaques and slowed the rate of decline in patients with mild cognitive impairment (MCI) or mild to moderate dementia due to Alzheimer's disease. Data were presented at the Alzheimer's Association International Conference in Chicago.

Compared with placebo, elenbecestat led to a 0.104 standard uptake value ratio (SUVR) reduction in 28 patients who received the PET imaging agent Neuraceq [18F]-florbetaben (p=0.011) and a 0.227 SUVR reduction in 7 patients who received Amyvid florbetapir (p=0.024). Elenbecestat also showed a mean 0.5-point improvement in Clinical Dementia Rating Sum of Boxes (CDR-SB) score vs. placebo (increase of 1.1 points vs. increase of 1.6 points), though no p-value was reported as this was an exploratory endpoint...